Replies to post #337783 on Amarin Corp Plc (AMRN)

[ramfan60]

Thanks Raf.... always appreciated!

[mrmainstreet]

Thanks for posting this. They cannot seem to grow scripts currently. Very disheartening.

Where are all the new patients who need Vascepa? What is the sales/marketing team even doing?

Generics are fairly flat around 10k, so why isn't the overall market size growing?

[ralphey]

gV kicking butt as insurers gleefully substitute and the company is silent not proactive not sending out letters to insurers regarding infringement not having reps contact insurance companies to provide education

AMRN needs to decide on the US market - -if you are going to have 7- 800 employees in the US then they need to do something to promote the med If you are just going to roll over then get this dead wood off the payroll -

Lead follow or get out of the way !!

[heysfguy]

RAF, this brings up a question about European sales. My current understanding is that Lovaza is not acceptable in Europe currently. If that’s the case doesn’t that bode especially well for V sales in Europe? Or perhaps my understanding is wrong. Would appreciate input.

[Invest83838]

Wow - 2 Big Weeks in a Row for Generic Vascepa

Guess there is no supply issues for HIKMA

HIKMA is kicking AMRN's butt

[MNBioMike]

You guys want to hear a joke?

So there’s this company, and they have 800 salespeople and an amazing drug, but only one drug - not 2, not 4, just 1. The sales team spends 40,000 hours a week selling this one drug and hasn’t increased sales in a year.

Isn’t that a good one?

[Rob777]

Thank you for posting every week.

[johngnatt]

Is it possible to breakdown Vaspeca prescription for TG vs CVD indication?

More importantly, the TG market is well established for 5- 7 years and unlikely to have increased.
So if we do the math, it may be easy.
At its pre reduce it peak, the prescription was around 700K / Q . Let us make it 3 mil total prescription for the year.

Today

Generic Vascepa is around 11k/ week = 600K.

Vascepa is around 80k/ week = 4.2 million.

How much fo this 4.2 mil is exclusively for high TG ? Will it be similar to pre- Reduce It? This makes the CVD indication only at 1.2 million, which is abysmal. How do you reconcile?

[Bolio98]

Thanks Raf.

[circuitcity]

Appreciate the info

[rafunrafun]

Sripts for week ending April 30, 2021.

Overall drug TRx are +0.6% w/w.

Vascepa
TRx 84,100; +0.3% w/w; +2.1% y/y
NRx 38,256; -0.6% w/w; +9.0% y/y
Ref 45,844; +1.1% w/w; -3.0% y/y

Generic Vascepa
TRx 9,630; -10.2% w/w; As % of total V: 10.3%
NRx 5,456; -7.3% w/w; As % of total V: 12.5%
Ref 4,174; -13.8% w/w; As % of total V: 8.3%

Lovaza (Generic & Brand)
TRx 61,712; +0.7% w/w; +4.8% y/y
NRx 30,565; +0.6% w/w; +14.9% y/y
Ref 31,147; +0.7% w/w; -3.4% y/y